Taysha Gene Therapies (TSHA) Cash & Equivalents (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Cash & Equivalents data on file, last reported at $276.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 137.24% year-over-year to $276.6 million; the trailing twelve-month figure through Mar 2026 stood at $276.6 million (up 137.24% YoY), and the FY2025 full-year result was $319.8 million, up 129.99% from the prior year.
• Cash & Equivalents slipped to $276.6 million in Q1 2026, from $319.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $319.8 million in Q4 2025 to a low of $36.9 million in Q3 2022.
• A 5-year average of $158.5 million and a median of $141.5 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 80.7% in 2022 and soared 344.68% in 2023, its largest moves.
• Tracing TSHA's Cash & Equivalents over 5 years: stood at $36.9 million in 2022, then soared by 289.63% to $143.9 million in 2023, then decreased by 3.41% to $139.0 million in 2024, then surged by 129.99% to $319.8 million in 2025, then decreased by 13.5% to $276.6 million in 2026.
• Business Quant data shows TSHA's Cash & Equivalents at $276.6 million in Q1 2026, $319.8 million in Q4 2025, and $297.3 million in Q3 2025.